AIIMS warns against the use of Remdesivir, other drugs: New Delhi’s All India Institute of Medical Sciences (AIIMS) has warned against the overuse of currently popular drugs for treating Covid-19 such as Remdesivir and Tocilizumab until more evidence that establishes their efficacy is found. The doctors also said Hydroxychloroquine has failed to show any efficacy in three randomised control trials, a critical requirement in evaluating new therapies. India, however, still recommends Hydroxychloroquine to treat mild cases of Covid-19. Read more here
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)